Neurotech International (ASX:NTI) has announced positive results from its recently completed 28-day Good Laboratory Practice oral toxicology studies evaluating its lead drug candidate NTI164. …
Neurotech says NTI164 shows positive tolerability in key preclinical toxicology studies
May 5, 2025 Australian Biotech
Latest Video
New Stories
-
Just because the system involves humans, it does not make it human
August 14, 2025 - - Latest News -
Australian company Mirugen secures backing to process cell technology
August 13, 2025 - - Latest News -
AccessCR’s awards celebrate partnerships between lived experience and science
August 13, 2025 - - Latest News -
Firebrick says Nasodine COVID-19 patent accepted in Europe
August 13, 2025 - - Australian Biotech -
Orthocell advances US rollout of nerve repair product Remplir
August 13, 2025 - - Australian Biotech -
AVITA Medical successfully completes Australian equity raise
August 13, 2025 - - Australian Biotech -
Experienced innovation leader joins AusBiotech as its Head of Investment
August 13, 2025 - - Australian Biotech